Medical News

Single Center Experience Evaluating and Initiating People wi...
AIDS

Despite novel challenges over half of our cohort initiated long-acting (LAI) cabotegravir/rilpivirine (CAB/RPV)....

02 Dec 2022

Subclinical Atherosclerosis as Detected by Carotid Ultrasoun...
HIV Med

The data showed that the current overall percentage of carotid impairments remains high. Colour-Doppler...

01 Dec 2022

Efficacy, Safety, and Tolerability of Isoniazid Preventive T...
AIDS

This systematic review and meta-analysis identified a significant reduction in the incidence of active TB, but not...

24 Nov 2022

Effectiveness and Safety of Dolutegravir and Raltegravir for...
J. Int. AIDS Soc.

These reassuring findings suggest that dolutegravir and raltegravir are effective and safe as preferred regimens in...

17 Nov 2022

Key Trials

NADIA Trial: Efficacy and Safety of Dolutegravir or Darunavir in Combination with Lamivudine plus either Zidovudine or Tenofovir for Second line HIV Treatment

NADIA trial assessed efficacy and safety of Dolutegravir or Darunavir in Combination with Lamivudine plus either Zidovudine or Tenofovir for 2nd...

QUATUOR Trial: Efficacy and Safety of a 4-days-on and 3-days-off Maintenance Treatment Strategy for Adults with HIV-1

ANRS 170 QUATUOR trial is the first prospective multicentre randomised trial to investigate the efficacy and safety of a 4-days-on and 3-days-off...

ENCORE 1 Study: Efficacy and Safety of Reduced Dose EFV With Standard Dose EFV In Combination with TDF And FTC As First-Line Treatment for HIV Infection

ENCORE 1 study is the first randomized study comparison of a reduced dose of efavirenz in antiretroviral naive, HIV-infected adults. The 48 weeks...

Impact of Azithromycin on ARES in Children with HIV and Chronic Lung Disease

The present study is the post hoc analysis of BREATHE trial, The analysis aimed to explored the risk factors for acute respiratory exacerbations in...

Our Publications

Antiretroviral-based Prevention Strategies in HIV

Today, antiretroviral therapy (ART) is not only known to keep HIV-infected patients alive but is also being harnessed as a strategy to prevent...

Antiretroviral Therapy – Current Recommendations

Advances in the treatment of HIV infection has resulted in a dramatic shift, from a deadly infectious disease to a chronic manageable condition....

Datasheet: Lopinavir and Ritonavir (40mg/10mg) Oral Pellets

Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This datasheet contains the entire...

Fast Facts: Lopinavir and Ritonavir (40 mg/10 mg) Oral Pellets

Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This booklet contains information about...

Patient Education

Live Healthier, Live Longer

This publication features commonly asked questions by HIV patients regarding HIV therapy, drug side-effects, Do’s and Don’ts while on HIV treatment....

Living with Hope

This publication features common questions which arise in HIV patients mind regarding HIV, diagnosis, transmission, treatment and drug side effects. ...

Slide Library

HIV - HCV Coinfection

This slide set covers the epidemiology, disease progression and management of HIV-HCV coinfection in the era of directly acting antivirals available...

 
Email this page
HIV - Pre-exposure Prophylaxis (PrEP): Guidance on PrEP Use

PrEP is the use of an antiretroviral medication by HIV-negative individuals to prevent them from acquiring HIV. These slides give an overview on the...

 
Email this page
HIV- Post-exposure Prophylaxis (PEP)

Post-exposure prophylaxis (PEP) is the method of preventing exposures of HIV to blood and body fluids and it is considered to be the most important...

 
Email this page
Isoniazid Preventive Therapy in HIV Infection

HIV is the strongest risk factor for developing tuberculosis (TB) disease in those with latent or new Mycobacterium tuberculosis infection....

 
Email this page

Infographics

Explore >>

Currently there is no content under this category.

Poll

Which is your preferred 3rd drug in a first-line regimen?

Efavirenz 600
50% (3 votes)
Efavirenz 400
17% (1 vote)
Dolutegravir
33% (2 votes)
Total votes: 6